Drug Profile
CSL 360
Alternative Names: anti-CD123 mAb; CSL360; IL-3RαLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator CSL
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Interleukin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Australia (IV, Infusion)
- 30 Sep 2009 CSL completes a phase I trial in Acute myeloid leukaemia in Australia
- 22 Jan 2009 CSL 360 is still in phase I trials for Acute myeloid leukaemia in Australia